Ascenta Capital
New York City, New Yorkascentacap.com
Overview
Ascenta Capital is a venture capital firm founded in 2023 that is focused on making concentrated investments in biotech companies. The firm partners with companies that have development candidates to help translate their preclinical science into early human safety and efficacy data, with a belief in the opportunity of multi-product platforms. It was co-founded by Dr. Evan Rachlin, formerly of Blackstone Life Sciences, and Dr. Lorence Kim, former CFO of Moderna.
Portfolio Companies
11
Website
ascentacap.comInvestments
| Company | Date | Stage | Lead |
|---|---|---|---|
| ARCYN Defense | Jul 2026 | Seed | Co-investor |
| TriveniBio | Jun 2026 | Series C | Lead |
| ARCYN Defense | Feb 2026 | Seed | Co-investor |
| Angitia Biopharmaceuticals | Feb 2026 | Series D | Co-investor |
| TRIANA Biomedicines | Dec 2025 | Series B | Lead |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
